Increased Risk of Second Primary Malignancy and Mortality at ten Years After Stem Cell Transplant for Multiple Myeloma: An Analysis of 14,532 Patients

Background The landscape for patients with multiple myeloma has improved dramatically over the last 15 years. Immunomodulatory imide drugs (IMiDs) have shown great efficacy in both the setting of initial therapy and as maintenance after autologous stem cell transplant (ASCT). Concern has arisen, how...

Descripción completa

Detalles Bibliográficos
Autores principales: Miles, Brittany, Mackey, James D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366185/
https://www.ncbi.nlm.nih.gov/pubmed/34422458
http://dx.doi.org/10.7759/cureus.16372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366185/
https://www.ncbi.nlm.nih.gov/pubmed/34422458
http://dx.doi.org/10.7759/cureus.16372

Ejemplares similares